Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
K5 Therapeutics from Leuven, company number BE0757718072, closed financial year 2025 with a result of € 261,735 after tax. For that financial year K5 Therapeutics recorded a gross margin of € 2.6 million and equity of € 3 million. Compared with financial year 2024, the result moved from € 187,917 to € 261,735. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.
€ 3 million
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 261,735
▲ 39% vs 2024
Profit after tax over the fiscal year.
€ 1 million
▲ 145% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 596,818.
People and assets in 2025
17.8
▲ 4.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.2 million
▲ 46% vs 2024
€ 122,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 64,080
▲ 19% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 131,551
▼ 60% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 365,602
▲ 60% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,752,970 | - | - | - | |
| Gross margin | € 1,224,339 | € 1,359,753 | € 1,846,089 | € 2,632,342 | ▲ 43% |
| Profit after taxes | € 885,725 | € 124,322 | € 187,917 | € 261,735 | ▲ 39% |
| Equity | € 2,385,244 | € 2,509,566 | € 2,697,483 | € 2,959,218 | ▲ 10% |
| Total debts | € 523,854 | € 699,327 | € 561,398 | € 599,783 | ▲ 7% |
| Cash | € 73,281 | € 111,977 | € 416,604 | € 1,021,803 | ▲ 145% |
| Retained profit | € 22,844 | € 147,166 | € 335,083 | € 596,818 | ▲ 78% |
| Balance sheet total | € 2,909,098 | € 3,208,893 | € 3,258,881 | € 3,559,001 | ▲ 9% |
| Employees (FTE) | 2.7 | 10.6 | 13.5 | 17.8 | ▲ 4.3 |
Key figures of K5 Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to K5 Therapeutics?
What happened at K5 Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 261,735 (▲ 39% vs 2024). Source: NBB ↗
- Jakob Busch-Petersen became a director. NBB
- Rita Balice Gordon became a director. NBB
- Anders Hinsby became a director. NBB
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 885,725 profit in 2022 to € 261,735 profit in 2025.
Paid € 8,500 in corporate taxes since 2022.
Best year ever: 2022, with € 885,725 profit.
On average € 147,900 of value added per employee in 2025.
A new publication or filing at K5 Therapeutics? We notify you, reason included.
Follow K5 TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind K5 Therapeutics are Jakob Busch-Petersen, Rita Balice Gordon and Anders Hinsby.
Directors
According to the 2025 annual accounts
Jakob Busch-Petersen
Director
since 2021
Rita Balice Gordon
Director
since 2021
Anders Hinsby
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics
€ -528,262 gross margin · 2025
AUGUSTINE THERAPEUTICS
€ -1.7 million gross margin · 2025
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Barracuda
Hosting
AMAZON-02 - Amazon.com, Inc., US
Domain
Domain
munatherapeutics.com
Registered
2019-04-17
Registrar
Key-Systems GmbH
Expires
2026-04-17
Website info
Features
Security
Network
Details
- Company number
- 0757.718.072
- VAT number
- BE 0757.718.072
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- K5 Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 November 2020
- Peppol
- Active · Active since 18 Dec 2025
- Contact
- munatherapeutics.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied